Olema Pharmaceuticals heads into its August 14 earnings report carrying one of the heavier short burdens in clinical-stage biotech — and a Street consensus that disagrees sharply with the bears.
Short interest is the defining feature of the positioning setup. Nearly one in five freely traded shares — 19.2% of the float — is currently sold short, a figure that has climbed roughly 14% over the past month. The recent history shows an abrupt step-up: short positions were running near 13 million shares in early July before jumping to around 15 million by mid-month and holding there. Yet the borrow market tells a calmer story. Availability is ample at roughly 289% of current short interest, well within the normal range, and cost to borrow has barely moved — holding near 0.54%, up less than 1% on the week. The ORTEX short score of 72.3 places OLMA in the 10th percentile of its sector on that metric, flagging elevated bearish positioning in context. But with borrow cheap and shares easy to source, there is no mechanical squeeze pressure building.
Options positioning adds a more defensive layer. Puts outnumber calls by almost two-to-one — a put/call ratio of 1.99 — though that reading is essentially in line with the elevated 20-day average of 1.98, reflecting a structural overhang of protective positioning rather than a fresh surge of pre-earnings hedging. The ratio peaked near 2.45 in late July and has since eased. The stock itself has drifted sideways, up 6% on the week to $11.94 but barely changed over the past month, suggesting the market is in a holding pattern ahead of the catalyst.
The analyst community and the shorts are pulling in opposite directions, and the gap is wide. Nine analysts carry buy ratings with a mean price target of $40.70 — more than three times the current price. That said, the most recent analyst activity, from May and March, reflects some caution: Guggenheim trimmed its target to $35 from $38, and Goldman Sachs cut to $27 from $38 in March, though both maintained buy ratings. JP Morgan raised its target to $58 in March, keeping Overweight. The bull case centres on palazestrant's differentiation in oral SERDs and the KAT6 inhibitor OP-3136's potential in a rapidly evolving space, with some pointing to acquisition interest as a floor. Bears argue the SERD market is overcrowded, OPERA-01's Phase 3 design lacks an interim analysis, and the company is burning cash in a competitive field with larger rivals. Institutional holders are well-known life-sciences specialists — Bain Capital Life Sciences, Paradigm Biocapital, Cormorant — who built or added positions in Q1. FMR added nearly 1.7 million shares through June 30, a meaningful endorsement from the largest holder.
Historical reactions to OLMA's prints have been volatile and predominantly negative. The prior three earnings events produced first-day moves of -8.6%, -6.7%, and -6.6%, with multi-day losses extending further in two of those cases. The June 2026 event was the exception, producing a 3.5% one-day gain and a 21% five-day rally — a reminder that clinical data surprises can sharply reverse the trend. The August 14 print will test whether pipeline progress on OP-3136 and any update on palazestrant's competitive positioning can shift a short thesis that has grown steadily more entrenched through the summer.
See the live data behind this article on ORTEX.
Open OLMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
